Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind and Placebo-controlled Single Ascending-dose Phase I Study (First-in-human) to Investigate the Safety, Tolerability and Pharmacokinetics of Contraloid Acetate (in Healthy Subjects).

NCT03944460 is registered in ClinicalTrials.gov with Prof. Dr. Dieter Willbold as lead sponsor.

NCT NCT03944460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03944460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind and Placebo-controlled Single Ascending-dose Phase I Study (First-in-human) to Investigate the Safety, Tolerability and Pharmacokinetics of Contraloid Acetate (in Healthy Subjects).
Lead sponsor
Prof. Dr. Dieter Willbold
Phase
Phase 1
Overall status
Completed
Start date
April 9, 2018
Completion date
July 27, 2018
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer dementia, alzheimer disease